SCH 900271

SCH 900271
Names
	Preferred IUPAC name 5-[3-(1-Methylcyclopropyl)propyl]-2H-pyrano[2,3-d]pyrimidine-2,4,7(1H,3H)-trione
Identifiers
CAS Number	915210-50-3 ;
3D model (JSmol)	Interactive image;
ChEMBL	ChEMBL2036958;
ChemSpider	28518389;
DrugBank	DB12433;
PubChem CID	56950369;
UNII	G2283XQ6VJ ;
CompTox Dashboard (EPA)	DTXSID00238609 ;
	InChI InChI=1S/C14H16N2O4/c1-14(5-6-14)4-2-3-8-7-9(17)20-12-10(8)11(18)15-13(19)16-12/h7H,2-6H2,1H3,(H2,15,16,18,19) Key: ARJKMWXLIHZLQZ-UHFFFAOYSA-N; InChI=1/C14H16N2O4/c1-14(5-6-14)4-2-3-8-7-9(17)20-12-10(8)11(18)15-13(19)16-12/h7H,2-6H2,1H3,(H2,15,16,18,19) Key: ARJKMWXLIHZLQZ-UHFFFAOYAP;
	SMILES O=C1C=C(CCCC2(CC2)C)C(C(NC(N3)=O)=O)=C3O1;
Properties
Chemical formula	C14H16N2O4
Molar mass	276.292 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

SCH 900271 is a nicotinic acid derivative designed to treat dyslipidemia. It reduced plasma free fatty acids levels, but without significant flushing, a side effect common with niacin that limits its usefulness. SCH 900271 is currently in human trials.^[1]

References[edit]

^ Palani, Anandan (November 2011). "Discovery of SCH 900271, a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia". ACS Medicinal Chemistry Letters. 3 (1): 63–8. doi:10.1021/ml200243g. PMC 4025820. PMID 24900372.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[Palani-1] Palani, Anandan (November 2011). "Discovery of SCH 900271, a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia". ACS Medicinal Chemistry Letters. 3 (1): 63–8. doi:10.1021/ml200243g. PMC 4025820. PMID 24900372.

[1]